Patent ID: 8642661
Filing Date: 2014-02-04
Classification: A61K,A61P

Abstract:
1. A combination comprising: (i) a therapeutically effective amount of a beta-3 adrenergic receptor agonist selected from the group consisting of solabegron and pharmaceutically acceptable salts thereof; and (ii) a therapeutically effective amount, or a sub-therapeutically effective amount, of a muscarinic receptor antagonist selected from the group consisting of tolterodine, oxybutynin, trospium, solifenacin, darifenacin, propiverine, fesoterodine, and pharmaceutically acceptable salts thereof, said combination being useful for relieving one or more symptoms of overactive bladder in a synergistic manner, versus the individual components (i) and (ii), wherein said one or more symptoms of overactive bladder are selected from the group consisting of frequency of urgency, nocturia, increase in urinary micturition frequency, and urinary incontinence.